ProNai: Corporate Presentation (ProNAi) - Feb 4, 2016 - "PNT2258-01: Safety and Tolerability Trial"; "Well Tolerated: Majority AEs = Grade 1 or 2; No drug related SAE's, No evidence of systemic immune response (i.e. TLR)"; "Significant exposures achieved: PNT2258 exposures meet/exceed those required for maximum anti-tumor efficacy in xenografts, Long exposure times with IV systemic delivery (t½ = 10-24 h)"
P1 data • Oncology
|